STOCK TITAN

Xilio Therapeutics Inc - XLO STOCK NEWS

Welcome to our dedicated news page for Xilio Therapeutics (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Xilio Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Xilio Therapeutics's position in the market.

Rhea-AI Summary
Xilio Therapeutics announces the promotion of Katarina Luptakova, M.D., to chief medical officer and Scott Coleman, Ph.D., to chief development officer. Martin Huber, M.D., will leave the company to pursue a CEO opportunity but will remain as an advisor. The promotions highlight the depth of Xilio's internal talent and its successful clinical development efforts. Luptakova brings extensive experience in clinical oncology drug development, while Coleman has a strong background in drug development and strategic thinking. Xilio's recent early clinical data shows promising results for its tumor-activated immuno-oncology therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
management
-
Rhea-AI Summary
Xilio Therapeutics CEO to participate in fireside chat at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
conferences
-
Rhea-AI Summary
Xilio Therapeutics, Inc. announces clinical trial collaboration with Roche to evaluate XTX101 in combination with atezolizumab in patients with colorectal cancer. The company also provides updates on its pipeline progress and financial results for Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
conferences
Xilio Therapeutics Inc

Nasdaq:XLO

XLO Rankings

XLO Stock Data

29.73M
12.39M
11.49%
56.53%
0.21%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Waltham

About XLO

xilio is a waltham, massachusetts-based biopharmaceutical company focused on defeating cancer. the company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, xilio, derived from the latin term, ex nihilo, meaning creation or big-bang. xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. to learn more, please visit www.xiliotx.com.